MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

NCT00371007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
DRUG: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks

Sponsor

Merck Sharp & Dohme LLC